Skip navigation
中文
English
DSpace
CRIS
首頁
單位
研究人員
研究成果檢索
分類瀏覽
單位
研究人員
研究成果檢索
學術出版
幫助
中文
English
NTU Scholars
國立臺灣大學
/
醫學院附設醫院 (臺大醫院)
/
新竹臺大分院
/
新竹臺大分院-新竹醫院
/
內科部-新竹臺大分院 (新竹醫院)
JEN-CHUNG KO
研究人員網路
瀏覽統計
Email 通知
RSS Feed
簡歷
研究成果
63
計畫
19
研究成果
(全部)
全部
期刊文章
回顧型論文
其他
顯示/隱藏過濾條件
依作者
5
jen-chung ko
4
meng-rui lee
3
li-ta keng
2
chao-chi ho
2
chong-jen yu
2
jann-yuan wang
2
wei-yu liao
1
chang, ching-i
1
chia-hao chang
1
chih-hsin yang
.
下一頁 >
主題
3
[sdgs]sdg3
1
adjuvant therapy; chemotherapy; early-stage nsclc; uracil-tegafur
1
afatinib; complementary dna; epidermal growth factor receptor; erlotinib; gefitinib; leucine; proline; serine; afatinib; antineoplastic agent; egfr protein, human; epidermal growth factor receptor; adult; aged; article; cancer chemotherapy; cancer resistance; cancer staging; cancer survival; clinical article; cohort analysis; dna sequence; drug efficacy; drug response; egfr gene; female; gene mutation; human; human tissue; lack of drug effect; lung adenocarcinoma; male; middle aged; priority journal; progression free survival; treatment planning; trend study; very elderly; genetics; lung adenocarcinoma; lung tumor; mortality; mutation; survival analysis; adenocarcinoma of lung; adult; afatinib; aged; aged, 80 and over; antineoplastic combined chemotherapy protocols; erbb receptors; female; humans; lung neoplasms; male; middle aged; mutation; neoplasm staging; survival analysis
1
egfr mutation-positive lung adenocarcinoma; afatinib; first-line therapy; prognostic factor; real-world study
依日期
1
2023
1
2021
1
2019
1
2018
1
2017
依類型
5
journal article
全文
5
no fulltext
關閉過濾條件
再查詢
作者:
sheng-kai liang
作者:
jin-yuan shih
第 1 到 5 筆結果,共 5 筆。
公開日期
標題
作者
來源出版物
scopus
WOS
全文
1
2023
Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early-stage non-small cell lung cancer patients
SHENG-KAI LIANG
; Wu, Chang-Wei; Chang, Ching-I; LI-TA KENG
; MENG-RUI LEE
; JANN-YUAN WANG
; JEN-CHUNG KO
; WEI-YU LIAO
; KUAN-YU CHEN
; CHAO-CHI HO
; JIN-YUAN SHIH
; CHONG-JEN YU
Cancer medicine
0
0
2
2021
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
SHENG-KAI LIANG
; LI-TA KENG
; CHIA-HAO CHANG
; Wen, Yueh-Feng; MENG-RUI LEE
; CHING-YAO YANG
; JANN-YUAN WANG
; JEN-CHUNG KO
; JIN-YUAN SHIH
; CHONG-JEN YU
Frontiers in Oncology
2
3
3
2019
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
SHENG-KAI LIANG
; JEN-CHUNG KO
; CHIH-HSIN YANG
; JIN-YUAN SHIH
Lung Cancer
27
25
4
2018
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study
SHENG-KAI LIANG
; MENG-RUI LEE
; WEI-YU LIAO
; CHAO-CHI HO
; JEN-CHUNG KO
; JIN-YUAN SHIH
Oncotarget
17
0
5
2017
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
SHENG-KAI LIANG
; MIN-SHU HSIEH
; MENG-RUI LEE
; LI-TA KENG
; JEN-CHUNG KO
; JIN-YUAN SHIH
Oncotarget
55
52
申請連結研究人員資料
以 ORCID 登入申請連結此個人資料
ORCID Login
Contact via feedback form
若您要聯絡網站管理員,請點選以下按鈕